within Pharmacolibrary.Drugs.V_Various.V09D_HepaticAndReticuloEndothelialSystem.V09DB02_Technetium99mtcMicrocoll;

model Technetium99mtcMicrocoll
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 0,
    adminDuration = 600,
    adminMass = 0.2 / 1000000,
    adminCount = 1,
    Vd = 0.001,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Technetium99mtcMicrocolloid</td></tr><tr><td>ATC code:</td><td>V09DB02</td></tr><td>route:</td><td>subcutaneous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>0.2</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0</td><td></td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Technetium (99mTc) microcolloid is a radiopharmaceutical used primarily for imaging in nuclear medicine. It is most commonly applied in sentinel lymph node mapping, liver-spleen scintigraphy, and bone marrow imaging. It is an approved and widely used diagnostic agent today.</p><h4>Pharmacokinetics</h4><p>No detailed pharmacokinetic studies (e.g., model-based PK parameters) have been published for technetium (99mTc) microcolloid in humans. Absorption/distribution are based on intended imaging organ after intravenous or subcutaneous administration, and elimination mainly occurs via the reticuloendothelial system and subsequent excretion.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V09DB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Technetium99mtcMicrocoll;
